Zhang Ping 4

What Happened

• Zhang Ping, a director of Gyre Therapeutics (GYRE), received a derivative award on June 10, 2026: an option or right to purchase 40,000 shares of common stock. The acquisition price is reported as $0.00 because this is an equity award (not an open-market purchase or sale).

Key Details

• Transaction date: June 10, 2026; Filing date: June 30, 2026 (appears to be filed late — Form 4 is normally due within two business days).
• Reported acquisition: 40,000 shares (derivative), reported price $0.00; transaction code: A (Award/Grant).
• Vesting: The option vests in 12 equal monthly installments through June 10, 2027, subject to continued service (per footnote).
• Shares owned after the transaction: Not specified in this filing.
• Footnote: Confirms this is a right to purchase 40,000 shares that vests monthly; no immediate stock sale or cashless exercise reported.

Context

• This is a grant of a derivative award (option/right to buy shares) rather than an outright purchase or sale. No cash changed hands at grant and the award will only convert into exercisable rights over time as it vests.
• Such director equity awards are common as compensation; they do not by themselves indicate buying or selling sentiment until vested/exercised or shares are sold. The late filing may be of interest to compliance-minded investors.